2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” Ocrelizumab may cause total body hair loss in some patients.
10 citations
,
February 1976 in “The Journal of Dermatology” γ‐Oryzanol ointment increases sebaceous gland activity and sebum production.
October 2024 in “Journal of the Endocrine Society” Ovarian stromal hyperplasia can cause high testosterone in postmenopausal women and is treated by removing the ovaries.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
2 citations
,
May 2012 in “Indian drugs” Finasteride, a hair loss treatment, works better and is more stable when delivered through specially prepared gels, leading to increased hair growth.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
January 1993 in “Проблемы Эндокринологии” Spironolactone effectively reduces symptoms of hyperandrogenism but has some side effects.
July 2018 in “Elsevier eBooks” Lichen Planopilaris is a hair loss condition best treated early with various medications, including hydroxychloroquine, to prevent permanent baldness.
5 citations
,
January 2017 in “Acta Endocrinologica” High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
April 2024 in “DAHUDER Medical journal” Ocrelizumab may cause pancreatitis in some patients.
5 citations
,
January 2024 in “Therapeutic Advances in Hematology” Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
169 citations
,
August 2004 in “Baillière's best practice & research. Clinical obstetrics & gynaecology/Baillière's best practice and research in clinical obstetrics and gynaecology” Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.
June 2025 in “British Journal of Dermatology” Denosumab may cause alopecia areata.
21 citations
,
August 1984 in “BJOG An International Journal of Obstetrics & Gynaecology” Ovarian function was similar in both treatment groups, but both caused excessive hair growth.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
Flubendazole in a nanoemulsion can potentially treat lung cancer and cryptococcal meningitis effectively and safely.
November 2024 in “Rheumatology Advances in Practice” Visceral leishmaniasis can mimic rheumatoid arthritis symptoms, especially in immunocompromised patients.
July 2022 in “L Endocrinologo” A 77-year-old woman with hair loss had high testosterone and 17OH-progesterone levels, but no significant findings on imaging.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
30 citations
,
February 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.
1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
November 2021 in “Elsevier eBooks” Antiandrogens are used to manage polycystic ovary syndrome by reducing androgen levels or controlling their effects, often combined with lifestyle changes and other treatments.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.